Protagonist Therapeutics (PTGX) Short Interest Ratio & Short Volume $56.32 +0.98 (+1.77%) As of 03:10 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Protagonist Therapeutics Short Interest DataProtagonist Therapeutics (PTGX) has a short interest of 5.21 million shares, representing 9.24% of the float (the number of shares available for trading by the public). This marks a -1.51% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.4, indicating that it would take 4.4 days of the average trading volume of 998,618 shares to cover all short positions.Current Short Interest5,210,000 sharesPrevious Short Interest5,290,000 sharesChange Vs. Previous Month-1.51%Dollar Volume Sold Short$246.33 millionShort Interest Ratio4.4 Days to CoverLast Record DateMay 31, 2025Outstanding Shares61,982,000 sharesShort Percent of Float9.24%Today's Trading Volume404,185 sharesAverage Trading Volume998,618 sharesToday's Volume Vs. Average40% Short Selling Protagonist Therapeutics? Sign up to receive the latest short interest report for Protagonist Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPTGX Short Interest Over TimePTGX Days to Cover Over TimePTGX Percentage of Float Shorted Over Time Protagonist Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/20255,210,000 shares $246.33 million -1.5%9.2%4.4 $47.28 5/15/20255,290,000 shares $234.93 million -13.6%9.4%4.2 $44.41 4/30/20256,120,000 shares $280.42 million +9.9%N/A5 $45.82 4/15/20255,570,000 shares $261.51 million +18.3%9.9%4.8 $46.95 3/31/20254,710,000 shares $227.78 million -8.2%8.4%4.4 $48.36 3/15/20255,130,000 shares $281.02 million +5.3%9.1%5.4 $54.78 2/28/20254,870,000 shares $183.06 million +15.4%8.6%6 $37.59 2/15/20254,220,000 shares $163.19 million +11.4%7.5%6.4 $38.67 1/31/20253,790,000 shares $143.26 million +3.3%N/A5.5 $37.80 1/15/20253,670,000 shares $139.24 million -3.4%N/A5.5 $37.94 Get the Latest News and Ratings for PTGX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20243,800,000 shares $146.68 million +5.3%N/A5.7 $38.60 12/15/20243,610,000 shares $148.30 million +6.2%N/A5.4 $41.08 11/30/20243,400,000 shares $148.92 million +3.0%N/A5 $43.80 11/15/20243,300,000 shares $135.66 million +0.6%N/A4.9 $41.11 10/31/20243,280,000 shares $150.36 million +9.3%N/A5.5 $45.84 10/15/20243,000,000 shares $142.92 million -14.8%N/A4.6 $47.64 9/30/20243,520,000 shares $158.40 million +9.0%N/A5.2 $45.00 9/15/20243,230,000 shares $151.87 million -1.5%N/A3.4 $47.02 8/31/20243,280,000 shares $140.68 million +5.8%N/A3.5 $42.89 8/15/20243,100,000 shares $125.83 million +6.9%N/A3.2 $40.59 7/31/20242,900,000 shares $108.58 million -11.0%N/A3.1 $37.44 7/15/20243,260,000 shares $119.81 million +59.8%N/A3.6 $36.75 6/30/20242,040,000 shares $70.69 million -34.6%N/A2.4 $34.65 6/15/20243,120,000 shares $104.18 million -7.7%N/A5.3 $33.39 5/31/20243,380,000 shares $95.15 million -2.6%N/A5.8 $28.15 5/15/20243,470,000 shares $109.20 million -7.0%N/A6.3 $31.47 4/30/20243,730,000 shares $93.66 million +6.0%N/A6.6 $25.11 4/15/20243,520,000 shares $93.56 million +2.3%N/A5.2 $26.58 3/31/20243,440,000 shares $99.52 million +0.6%N/A4.6 $28.93 3/15/20243,420,000 shares $99.11 million +16.3%N/A4.7 $28.98 2/29/20242,940,000 shares $89.32 million +5.8%N/A3.6 $30.38 2/15/20242,780,000 shares $78.48 million +6.5%N/A3.5 $28.23 1/31/20242,610,000 shares $65.28 million +2.4%N/A3.2 $25.01 1/15/20242,550,000 shares $66.05 million +8.5%N/A3.5 $25.90 12/31/20232,350,000 shares $53.89 million -41.0%N/A3.3 $22.93 12/15/20233,980,000 shares $83.86 million +9.3%N/A5.6 $21.07 11/30/20233,640,000 shares $66.28 million -0.3%N/A5.4 $18.21 11/15/20233,650,000 shares $59.46 million -7.4%N/A5.7 $16.29 10/31/20233,940,000 shares $57.29 million +15.5%N/A6 $14.54 10/15/20233,410,000 shares $52.65 million +8.3%N/A5.3 $15.44[No Brainer Gold Play]: “Show me a better investment.” (Ad)A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Click here to get Garrett’s Top Four picks now. 9/30/20233,150,000 shares $52.54 million +12.5%N/A4.5 $16.68 9/15/20232,800,000 shares $50.12 million +1.8%N/A3 $17.90 8/31/20232,750,000 shares $54.51 million -9.2%N/A2.8 $19.82 8/15/20233,030,000 shares $56.84 million +2.0%N/A2.8 $18.76 7/31/20232,970,000 shares $57.62 million -10.5%N/A2.7 $19.40 7/15/20233,320,000 shares $70.55 million +4.4%N/A2.8 $21.25 6/30/20233,180,000 shares $87.83 million +18.2%N/A2.7 $27.62 6/15/20232,690,000 shares $77.15 million -12.1%N/A2.5 $28.68 5/31/20233,060,000 shares $79.77 million -15.0%N/A2.5 $26.07 5/15/20233,600,000 shares $93.49 million -3.2%N/A2.2 $25.97 4/30/20233,720,000 shares $84.07 million -14.7%N/A2.2 $22.60 4/15/20234,360,000 shares $81.71 million +0.5%N/A2.5 $18.74 3/31/20234,340,000 shares $99.82 million -16.1%N/A2.6 $23.00 3/15/20235,170,000 shares $124.34 million +88.7%N/A3.2 $24.05 2/28/20232,740,000 shares $44.44 million +5.4%6.3%1.9 $16.22 2/15/20232,600,000 shares $42.43 million +2.0%6.0%2.5 $16.32 1/31/20232,550,000 shares $33.89 million +25.6%5.9%2.7 $13.29 1/15/20232,030,000 shares $24.71 million +14.0%4.7%2.4 $12.17 12/30/20221,780,000 shares $19.42 million -4.3%4.1%2.3 $10.91 12/15/20221,860,000 shares $17.73 million +6.9%4.3%2.4 $9.53 11/30/20221,740,000 shares $13.76 million -4.4%4.0%2.2 $7.91 11/15/20221,820,000 shares $14.63 million -7.6%4.2%2.4 $8.04 10/31/20221,970,000 shares $15.96 million -11.7%4.5%2.5 $8.10 10/15/20222,230,000 shares $17.82 million -8.2%5.1%2.6 $7.99 9/30/20222,430,000 shares $20.48 million -13.5%5.6%2.7 $8.43 9/15/20222,810,000 shares $23.24 million +9.3%6.5%2.8 $8.27 8/31/20222,570,000 shares $22.41 million -11.4%5.9%2.4 $8.72 8/15/20222,900,000 shares $32.86 million -31.6%6.7%2.7 $11.33 7/31/20224,240,000 shares $42.19 million -13.1%N/A3.5 $9.95 7/15/20224,880,000 shares $46.16 million +2.3%N/A3.5 $9.46 6/30/20224,770,000 shares $37.73 million +18.4%N/A3.4 $7.91 6/15/20224,030,000 shares $30.14 million +18.9%N/A3 $7.48 5/31/20223,390,000 shares $29.70 million +1.5%N/A2.9 $8.76 5/15/20223,340,000 shares $29.43 million +1.5%N/A2.9 $8.81 4/30/20223,290,000 shares $29.91 million +20.5%N/A3.1 $9.09 4/15/20222,730,000 shares $54.46 million -16.3%N/A3.3 $19.95 3/31/20223,260,000 shares $77.20 million -17.5%N/A4.6 $23.68 3/15/20223,950,000 shares $101.99 million -0.8%N/A5.7 $25.82 2/28/20223,980,000 shares $96.63 million -19.1%N/A5.6 $24.28 2/15/20224,920,000 shares $141.35 million +25.5%N/A7.3 $28.73 1/31/20223,920,000 shares $114.82 million +9.5%N/A6.4 $29.29 1/15/20223,580,000 shares $128.74 million +10.2%N/A5.9 $35.96 12/31/20213,250,000 shares $111.15 million +2.2%N/A2.4 $34.20 12/15/20213,180,000 shares $97.12 million +2.6%N/A2.2 $30.54 11/30/20213,100,000 shares $104.22 million -17.6%7.3%1.6 $33.62 11/15/20213,760,000 shares $134.38 million -15.1%8.8%1.9 $35.74 10/29/20214,430,000 shares $138.04 million +18.5%10.5%2.3 $31.16 10/15/20213,740,000 shares $115.83 million +2.8%8.9%2 $30.97 9/30/20213,640,000 shares $64.50 million +27.3%8.7%2.1 $17.72 9/15/20212,860,000 shares $132.90 million -6.5%6.8%3 $46.47Trump wipes out trillions overnight… (Ad)Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.Whether you take some of that wealth for yourself depends on if you watch this controversial exposé 8/31/20213,060,000 shares $148.41 million -4.4%7.3%7.3 $48.50 8/13/20213,200,000 shares $152.61 million +5.6%7.6%7.3 $47.69 7/30/20213,030,000 shares $149.77 million -11.1%7.3%6.9 $49.43 7/15/20213,410,000 shares $150.93 million -1.7%8.3%8.1 $44.26 6/30/20213,470,000 shares $155.73 million -1.4%8.5%8.5 $44.88 6/15/20213,520,000 shares $134.29 million -3.8%8.6%9.3 $38.15 5/28/20213,660,000 shares $128.50 million -6.2%9.7%11.6 $35.11 5/14/20213,900,000 shares $113.10 million +26.2%N/A12.2 $29.00 4/30/20213,090,000 shares $92.67 million +1.6%N/A9.2 $29.99 4/15/20213,040,000 shares $79.01 million +0.3%N/A9.1 $25.99 3/31/20213,030,000 shares $76.69 million +5.6%N/A8.5 $25.31 3/15/20212,870,000 shares $88.97 million +3.6%N/A6.4 $31.00 2/26/20212,770,000 shares $66.45 million -0.4%N/A5.6 $23.99 2/12/20212,780,000 shares $69.75 million +1.5%N/A5.9 $25.09 1/29/20212,740,000 shares $58.25 million -13.6%N/A5.7 $21.26 1/15/20213,170,000 shares $72.43 million -7.9%N/A6.6 $22.85 12/31/20203,440,000 shares $68.77 million +28.4%N/A7.6 $19.99 12/15/20202,680,000 shares $56.07 million +6.8%N/A6.6 $20.92 11/30/20202,510,000 shares $59.86 million -1.6%N/A6.9 $23.85 11/15/20202,550,000 shares $56.64 million No ChangeN/A7.2 $22.21 10/30/20202,550,000 shares $47.15 million -6.9%N/A7.2 $18.49 10/15/20202,740,000 shares $57.46 million -16.5%N/A7.9 $20.97 9/30/20203,280,000 shares $64.12 million +45.8%N/A9.5 $19.55 9/15/20202,250,000 shares $48.74 million +16.0%N/A6.3 $21.66 8/31/20201,940,000 shares $43.46 million +12.1%N/A5.4 $22.40 8/14/20201,730,000 shares $27.14 million +8.8%N/A4.2 $15.69 7/31/20201,590,000 shares $25.01 million +15.2%N/A2.8 $15.73 7/15/20201,380,000 shares $21.51 million +4.6%N/A1.3 $15.59 6/30/20201,320,000 shares $23.31 million -9.6%N/A1.2 $17.66 6/15/20201,460,000 shares $23.51 million +29.2%N/A1.4 $16.10 PTGX Short Interest - Frequently Asked Questions What is Protagonist Therapeutics' current short interest? Short interest is the volume of Protagonist Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 31st, investors have sold 5,210,000 shares of PTGX short. 9.24% of Protagonist Therapeutics' shares are currently sold short. Learn More on Protagonist Therapeutics' current short interest. What is a good short interest ratio for Protagonist Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTGX shares currently have a short interest ratio of 4.0. Learn More on Protagonist Therapeutics's short interest ratio. Which institutional investors are shorting Protagonist Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Protagonist Therapeutics: Jane Street Group LLC, Caption Management LLC, Jane Street Group LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Protagonist Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.24% of Protagonist Therapeutics' floating shares are currently sold short. Is Protagonist Therapeutics' short interest increasing or decreasing? Protagonist Therapeutics saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 5,210,000 shares, a decrease of 1.5% from the previous total of 5,290,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Protagonist Therapeutics' short interest compare to its competitors? 9.24% of Protagonist Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Protagonist Therapeutics: Dr. Reddy's Laboratories Limited (1.74%), Ascendis Pharma A/S (9.28%), Moderna, Inc. (19.23%), Viatris Inc. (4.33%), Qiagen (2.96%), Blueprint Medicines Co. (9.93%), Roivant Sciences Ltd. (10.63%), Revolution Medicines, Inc. (11.86%), Verona Pharma plc (9.37%), BridgeBio Pharma, Inc. (15.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Protagonist Therapeutics stock? Short selling PTGX is an investing strategy that aims to generate trading profit from Protagonist Therapeutics as its price is falling. PTGX shares are trading down $1.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Protagonist Therapeutics? A short squeeze for Protagonist Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTGX, which in turn drives the price of the stock up even further. How often is Protagonist Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTGX, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies Dr. Reddy's Laboratories Short Interest Ascendis Pharma A/S Short Interest Moderna Short Interest Viatris Short Interest Qiagen Short Interest Blueprint Medicines Short Interest Roivant Sciences Short Interest Revolution Medicines Short Interest Verona Pharma Short Interest BridgeBio Pharma Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTGX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
